• 1.

    Levey AS, et al.. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139:137147.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Chin MP, et al.. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail 2014; 20:953958.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Bakris GL, et al.. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015; 314:884894.

  • 4.

    Klahr S, et al.. Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877884.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Lewis JB. Blood pressure control in chronic kidney disease: Is less really more? J Am Soc Nephrol 2010; 21:10861092.

  • 6.

    Townsend RR. Blood pressure targets in CKD. Adv Chronic Kidney Dis 2015; 22:96101.

  • 7.

    Kovesdy CP, et al.. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014; 174:14421449.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Anderson AH, et al.. Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: A cohort study. Ann Intern Med 2015; 162:258265.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Taler SJ, et al.. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013; 62:201213.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Verbeke F, et al.. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 2014; 29:490496.

    • Search Google Scholar
    • Export Citation
  • 11.

    James PA, et al.. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507520.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Wright JT Jr, et al.. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:21032116.

  • 13.

    The Collaborative Study Group, Lewis EJ, et al.. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:14561462.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Ruggenenti PI, et al.. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359364.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Brenner BM, et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861869.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Jafar TH, et al.. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann Intern Med 2001; 135:7387.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:29812997.

    • Search Google Scholar
    • Export Citation
  • 18.

    Wright JT Jr, et al.. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288:24212431.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Barnett AH1, et al.. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:19521961.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Mann JF, et al.. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547553.

    • Crossref
    • Search Google Scholar
    • Export Citation

Disparities in the Treatment of CKD and Efforts to Slow Progression

  • 1 Moro Salifu, MD, is professor and chair of the department of medicine, SUNY Downstate Medical Center in Brooklyn, and Susanne B. Nicholas, MD, MPH, PhD, is associate professor of medicine in the divisions of nephrology and endocrinology, department of medicine, David Geffen School of Medicine at the University of California.
Restricted access
Save